Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes

Jean, Myriam; Alameh, Mohamad-Gabriel; Jesús, Diogo; Thibault, Marc; Lavertu, Marc; Darras, Vincent; Nelea, Monica; Buschmann, Michael D.; Merzouki, Abderrazzak

doi:10.1016/j.ejps.2011.10.029

Cited by 65 publications

(37 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jean et al found that SC administration of Ch/pVax1-4sFGF-2 or Ch/pVax1-PDGF-bb complexes lead to the expression and distribution of high levels of FGF-2 and PDGF-BB recombinant proteins in serum, and the IM administration induced a rapid production of specific antibodies, which is promising for the development of prophylactic or therapeutic vaccines [95]. The same research group described the ability of Ch based complexes to deliver the pVax1-GLP-1 plasmid encoding the native recombinant GLP-1 protein in a diabetic rat model [96].…”

Section: Other Delivery Routesmentioning

confidence: 99%

Low Molecular Weight Chitosan (LMWC)-based Polyplexes for pDNA Delivery: From Bench to Bedside

et al. 2014

View full text Add to dashboard Cite

Non-viral gene delivery vectors are emerging as a safer alternative to viral vectors. Among natural polymers, chitosan (Ch) is the most studied one, and low molecular weight Ch, specifically, presents a wide range of advantages for non-viral pDNA delivery. It is crucial to determine the best process for the formation of Low Molecular Weight Chitosan (LMWC)-pDNA complexes and to characterize their physicochemical properties to better understand their behavior once the polyplexes are administered. The transfection efficiency of Ch based polyplexes is relatively low. Therefore, it is essential to understand all the transfection process, including the cellular uptake, endosomal escape and nuclear import, together with the parameters involved in the process to improve the design and development of the non-viral vectors. The aim of this review is to describe the formation and characterization of LMWC based polyplexes, the in vitro transfection process and finally, the in vivo applications of LMWC based polyplexes for gene therapy purposes.

show abstract

Section: Other Delivery Routesmentioning

confidence: 99%

Low Molecular Weight Chitosan (LMWC)-based Polyplexes for pDNA Delivery: From Bench to Bedside

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Several groups have explored alternative strategies to bypass the limitations of incretin hormones in vivo [16,[31][32][33]. Among these methods, gene therapy provides a promising approach to regulate stability and efficacy of exendin-4.…”

Section: Liver Toxicity Evaluation In Pam-abp/chimeric Dnatreated Micementioning

confidence: 99%

Enhanced Incretin Effects of Exendin-4 Expressing Chimeric Plasmid Based On Two-Step Transcription Amplification System with Dendritic Bioreducible Polymer for the Treatment of Type 2 Diabetes

2013

J Gene Ther

View full text Add to dashboard Cite

Glucagon-like peptide 1 (GLP-1) agonist, exenxdin-4, is currently being advanced as a promising diabetes remedy via a variety of incretin actions similar with GLP-1. In this study, we investigated an effective anti-diabetic therapy via exendin-4 expressing chimeric plasmid based on two-step transcription amplification (TSTA) system with dendrimer-type bioreducible polymer for more improved incretinbased gene therapy. Arginine-grafted poly (cystaminebisacrylamidediaminohexane) (ABP)-conjugated poly (amido amine) (PAMAM) dendrimer (PAM-ABP) was used as gene carrier. PAM-ABP/chimeric DNA polyplex was markedly elevated exendin-4 expression in ectopic cells as well as increased insulin production through an enhanced activation of protein kinase K (PKA) induced by up-regulation of exendin-4-stimulated cyclic adenosine monophosphate (cAMP) in pancreatic β-cell. Consistent with these results, intravenous administration of PAM-ABP/chimeric DNA polyplex improved glucoregulotory effects, as well as increased insulin secretion by high expression of exendin-4 in blood in type 2 diabetic mice with no any toxicity. Our exendin-4 system can be attributed to provide a potential diabetes therapeutic agent for improved incretin gene therapy.

show abstract

“…16 CMs have been applied in the oral, 9 parenteral, 17 and nasal delivery 10,18,19 of encapsulated vaccine, DNA, or small interfering ribonucleic acid transfection studies. [20][21][22][23] Biodegradability, biocompatibility, and safety of CMs Biodegradability and biocompatibility play important roles in the metabolic process of chitosan in the body. It has been suggested that for systemic absorption a suitable MW (30-40 kDa) is essential for renal clearance dependent on the type of the polymer.…”

Section: Chitosan Microspheres (Cms)mentioning

confidence: 99%

Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review

Islam¹,

Firdous²,

Choi³

et al. 2012

IJN

View full text Add to dashboard Cite

Chitosan, a natural biodegradable polymer, is of great interest in biomedical research due to its excellent properties including bioavailability, nontoxicity, high charge density, and mucoadhesivity, which creates immense potential for various pharmaceutical applications. It has gelling properties when it interacts with counterions such as sulfates or polyphosphates and when it crosslinks with glutaraldehyde. This characteristic facilitates its usefulness in the coating or entrapment of biochemicals, drugs, antigenic molecules as a vaccine candidate, and microorganisms. Therefore, chitosan together with the advance of nanotechnology can be effectively applied as a carrier system for vaccine delivery. In fact, chitosan microspheres have been studied as a promising carrier system for mucosal vaccination, especially via the oral and nasal route to induce enhanced immune responses. Moreover, the thiolated form of chitosan is of considerable interest due to its improved mucoadhesivity, permeability, stability, and controlled/extended release profile. This review describes the various methods used to design and synthesize chitosan microspheres and recent updates on their potential applications for oral and nasal delivery of vaccines. The potential use of thiolated chitosan microspheres as next-generation mucosal vaccine carriers is also discussed.

show abstract

Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes

Cited by 65 publications

References 92 publications

Low Molecular Weight Chitosan (LMWC)-based Polyplexes for pDNA Delivery: From Bench to Bedside

Low Molecular Weight Chitosan (LMWC)-based Polyplexes for pDNA Delivery: From Bench to Bedside

Enhanced Incretin Effects of Exendin-4 Expressing Chimeric Plasmid Based On Two-Step Transcription Amplification System with Dendritic Bioreducible Polymer for the Treatment of Type 2 Diabetes

Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review

Contact Info

Product

Resources

About